In some mammals, the timing of the normally continuous embryonic development can be altered to improve the chances of survival for both the embryo and the mother. This mechanism to temporarily slow development, called embryonic diapause, often happens at the blastocyst stage, just before the embryo implants in the uterus.

During diapause, the embryo remains free-floating and pregnancy is extended. This dormant state can be maintained for weeks or months before development is resumed, when conditions are favorable. Although not all mammals use this reproductive strategy, the ability to pause development can be triggered experimentally. Whether human cells can respond to diapause triggers remained an open question.

Now, a study by the labs of Aydan Bulut-Karslıoğlu at the Max Planck Institute for Molecular Genetics in Berlin and Nicolas Rivron at the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences in Vienna, has identified that the molecular mechanisms that control embryonic diapause also seem to be actionable in human cells.

NEW YORK — In a groundbreaking development, scientists have created a revolutionary method to track the spread of cancer throughout the body, potentially paving the way for more effective treatments against this devastating disease. The new technology, developed by researchers at Cold Spring Harbor Laboratory and Weill Cornell Medicine in New York, uses genetic “barcodes” to monitor the movement of individual cancer cells, providing unprecedented insights into the process of metastasis.

Imagine being one cartwheel away from changing your appearance. One flip, and your brunette locks are platinum blond. That’s not too far from what happens in some prokaryotes, or single-cell organisms, such as bacteria, that undergo something called inversions.

A study led by scientists at Stanford Medicine has shown that inversions, which cause a physical flip of a segment of DNA and change an organism’s genetic identity, can occur within a single gene, challenging a central dogma of biology — that one gene can code for only one protein.

“Bacteria are even cooler than I originally thought, and I’m a microbiologist, so I already thought they were pretty cool,” said Rachael Chanin, PhD, a postdoctoral scholar in hematology. Microbiologists have known for decades that bacteria can flip small sections of their DNA to activate or deactivate genes, Chanin said. To the team’s knowledge, however, those somersaulting pieces have never been found within the confines of a single gene.

Robert C Williams performed genetic analysis to understand how the HLA and SLC16A11 genes affect Type 2 diabetes in Indigenous Americans.

GC Therapeutics’ plug-and-play stem cell programming platform aims to reduce cell therapy development time by up to 100 times.

Cell therapies have revolutionized the treatment of certain disease areas; however, challenges in scaling these therapies…

---

Cell therapy startup GC Therapeutics (GCTx) has emerged from the lab of renowned geneticist George Church, securing a $65 million Series A funding round that brings the total raised by the company to a cool $75 million. The company is on a mission to enable the next generation of cell therapies through its proprietary TFome platform, which GCTx claims is the first plug-and-play induced pluripotent stem cell (iPSC) cellular programming platform.

Developed by a team of scientists in Professor Church’s lab of at Harvard Medical School and the Wyss Institute, TFome aims to help streamline the complex, error-prone and costly process of cell therapy development by accelerating production and enhancing the quality of cell therapies across a wide range of disease areas. The power of the platform lies in its ability to harness transcription factors, the proteins that regulate gene expression and determine cell fate. By precisely controlling these factors, the platform can guide stem cells to differentiate into any desired cell type in a highly efficient and scalable manner.

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic disorders and cancer due to its huge potential in gene expression regulation. However, the efficient delivery and safety of short interfering RNA (siRNA) remain key challenges for its clinical application.

Summary: The largest and most diverse study on recessive genetic changes in developmental disorders reveals that over 80% of cases caused by recessive variants are linked to known genes. Researchers analyzed data from nearly 30,000 families and found that a shift in focus from gene discovery to interpreting changes in known genes could double diagnosis rates.

The study highlights the importance of genetic background in diagnosis and suggests that some patients may have multiple contributing genetic factors. These findings could lead to more personalized and accurate diagnoses for families affected by developmental disorders.